{"filings":[{"id":96605,"accession_number":"0001213900-26-052036","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Apimeds Pharmaceuticals appoints Sungjoon Chae as Co-CEO","event_type":"leadership","confidence":"high","bullets":["Sungjoon Chae appointed Co-CEO effective May 4, 2026, pursuant to a stockholder nomination.","No family relationships or related party transactions with company officers or directors.","Compensation terms for Chae have not yet been determined; will be disclosed when finalized.","Chae holds a Master of Architecture in Urban Design from Harvard University and specializes in large-scale real estate and urban regeneration.","Existing CEO Dr. Vin Menon continues as CEO; Chae serves as Co-CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96604,"accession_number":"0001213900-26-051125","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["1.01","5.02","8.01","9.01"],"status":"ready","headline":"Apimeds settles merger dispute; Lokahi provides $4M working capital; board to transition","event_type":"other_material","confidence":"high","bullets":["Settlement resolves all disputes from Dec 2025 Merger Agreement; Lokahi retains Apitox program assets valued at ~$2.2M.","Lokahi provides $4M working capital to Company and forgives $750k advance; 51% of Lokahi stock to be distributed to Emerson.","Newco formed as wholly owned subsidiary, to be spun off within 12 months; 10% of net financing proceeds allocated to Newco.","Board changes: Stockholder Consents voided; Koo to resign; interim board of three; then three new independent directors appointed by Inscobee.","Forbearance Agreement with Alto Opportunity Master Fund extends forbearance on $11M note defaults through June 30, 2026, subject to conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96603,"accession_number":"0001213900-26-046671","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Apimeds gets NYSE American delisting notice for late 10-K; trading halt continues","event_type":"regulatory","confidence":"high","bullets":["Received NYSE American notice on April 17, 2026 for failure to file 2025 10-K on time.","Has initial 6-month cure period until October 15, 2026; expects to file 10-K by April 30.","Common stock trades with '.LF' designation; trading halt from April 2 remains in effect.","If not cured, NYSE may grant up to 6 additional months or commence delisting procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96602,"accession_number":"0001213900-26-044657","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Apimeds expects NYSE notice for late 10-K filing; targets April 30","event_type":"regulatory","confidence":"high","bullets":["Filed Form 12b-25 on March 31, 2026 for FY 2025 10-K; will not file within 15-day extension.","Expects NYSE American non-compliance notice due to failure to timely file 10-K.","Plans to file 10-K by April 30, 2026; no assurance given.","Delay driven by ongoing preparation of financial statements and audit completion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96601,"accession_number":"0001213900-26-042017","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K/A","filed_at":"2026-04-09T23:59:59+00:00","items":["5.02","5.03","8.01","9.01"],"status":"ready","headline":"Apimeds: Majority stockholder consent to remove directors/officers is null and void","event_type":"other_material","confidence":"high","bullets":["Inscobee Inc. and Apimeds, Inc. attempted written consent to remove directors Kogan, Koo, O’Donnell, Weintraub and officers Menon (CEO) and Frim (CFO).","Company determined consent invalid due to violations of irrevocable proxy, consent waiver, and anti-frustration covenant in Support Agreement.","Support Agreement expressly states any action taken in violation is null and void; consent void ab initio.","Company will proceed with actions described in Schedule 14C Information Statement filed Feb 27, 2026, mailed March 5, 2026.","This Amendment No. 1 clarifies the previously reported actions are of no force or effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110642,"accession_number":"0001213900-26-034786","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["5.02","5.03","8.01","9.01"],"status":"ready","headline":"Apimeds faces hostile takeover attempt by Inscobee; company says consent void, files emergency action","event_type":"litigation","confidence":"high","bullets":["On March 20, 2026, Inscobee and Apimeds Korea claimed to remove all four directors and CEO/CFO via written consent.","Company states the consent violates the irrevocable proxy granted under the Support Agreement from Dec 1, 2025.","Inscobee used 6,416,365 shares subject to proxy; without those, consent lacks majority under Delaware law.","Company will file emergency action in Delaware Court of Chancery under 8 Del. C. § 225 to void consent.","Purported new board approved business expansions without authorization; company disputes them."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110641,"accession_number":"0001213900-26-033832","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["5.02","8.01","5.03","9.01"],"status":"ready","headline":"Apimeds US board and CEO ousted; new board approves expansion into Korean cosmetics and photo booth","event_type":"leadership","confidence":"high","bullets":["Majority stockholders removed directors Elona Kogan, Jakap Koo, Carol O’Donnell, Dr. Bennett Weintraub via written consent.","CEO Vin Menon and CFO Erick Frim removed; Youngjik Cho appointed CEO, Junyoung Yu as Secretary.","New board approved non-binding MOUs with Assemble, Hilluck (cosmetics distribution) and LK Ventures (Life4Cuts photo booth platform).","Company delays previously announced 1-for-10 reverse stock split; board will continue to evaluate timing.","MindWave issued unauthorized press release challenging the consent; company intends to vigorously defend validity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110640,"accession_number":"0001213900-26-028332","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Apimeds Pharmaceuticals to effect 1-for-10 reverse stock split on March 26, 2026","event_type":"other_material","confidence":"high","bullets":["Stockholders approved 1-for-10 reverse stock split via written consent in December 2025.","Reverse split effective 12:01 a.m. ET March 26, 2026; trading begins on split-adjusted basis same day.","Every 10 pre-split shares convert to 1 share; new CUSIP 03771D201.","Company expects to file charter amendment with Delaware Secretary of State around March 25."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110638,"accession_number":"0001213900-26-017323","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K/A","filed_at":"2026-02-17T23:59:59+00:00","items":["9.01","2.01"],"status":"ready","headline":"MindWave posts six-month net loss $6.6M on zero revenue; digital assets $132.3M","event_type":"other_material","confidence":"high","bullets":["Net loss $6.6M for six months ended Sep 30, 2025 vs net income $57.8M in prior year period.","No revenue from operations; digital assets at fair value $132.3M (incl. restricted).","Total equity $132.3M, zero liabilities; unrealized loss $9.1M from digital asset remeasurement.","Financials filed as Exhibit 99.1 for reverse merger with Apimeds (APUS) previously reported.","Company holds crypto tokens ($NILA) and generates gains mainly from sale of digital assets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110639,"accession_number":"0001213900-26-000464","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Apimeds Pharmaceuticals removes director Erik Emerson via stockholder vote","event_type":"leadership","confidence":"high","bullets":["Erik Emerson removed from board of directors effective December 30, 2025.","Removal effected by majority stockholder vote, with or without cause.","Remaining board: Elona Kogan, Jakap Koo, Carol O'Donnell, Dr. Bennett Weintraub."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127268,"accession_number":"0001213900-25-119894","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Two directors resign from Apimeds Pharmaceuticals board effective December 5, 2025","event_type":"leadership","confidence":"high","bullets":["Dr. Vin Menon and Amir A. Dossal resigned from the Board of Directors on December 5, 2025.","Resignations were not due to any disagreement with the company's operations, policies, or practices.","Dr. Vin Menon remains CEO of the company; no replacements for the vacant board seats announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127264,"accession_number":"0001213900-25-119893","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K/A","filed_at":"2025-12-10T23:59:59+00:00","items":["1.01","3.03","5.03","9.01"],"status":"ready","headline":"Apimeds corrects Merger Agreement errors: Preferred Stock issuance rises to 90.9% of equity","event_type":"m_and_a","confidence":"high","bullets":["Corrected Merger Agreement removes Sections 2.05(b)/(d) (director appointment).","Common Stock Cap corrected from 29.9% to 0% of Acquiror Common Stock outstanding.","Preferred Stock issuable to Company stockholders corrected from 61% to 90.9% of fully diluted equity.","Corrected Certificate of Designation increases Series A Preferred designated shares from 7,263,865 to 7,477,017.","Amendment to Securities Purchase Agreement extends Initial Closing date and expands investor notification rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127267,"accession_number":"0001213900-25-117173","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2025-12-02T23:59:59+00:00","items":["1.01","2.01","2.03","3.02","5.01","5.02","5.03","7.01","9.01"],"status":"ready","headline":"Apimeds Pharmaceuticals US completes merger with MindWave Innovations, issues 90.9% equity to MindWave holders","event_type":"m_and_a","confidence":"high","bullets":["On Dec 1, 2025, Apimeds (APUS) merged with MindWave Innovations, with MindWave surviving as wholly owned subsidiary.","MindWave stockholders received 29.9% of Apimeds common stock and 61% convertible preferred (as-converted), totaling 90.9% of post-merger equity.","Apimeds entered a $120.9M convertible note financing with 8% OID, issuing senior convertible notes.","CEO Erik Emerson resigned, replaced by Dr. Vin Menon; two new directors appointed.","Apimeds will effect a 1-for-10 reverse stock split and increase equity plan shares to 2,096,679."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127266,"accession_number":"0001213900-25-112184","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Apimeds boosts CEO salary to $500K and adds 24-month severance with equity vesting","event_type":"leadership","confidence":"high","bullets":["CEO Erik Emerson's annual base salary increased to $500,000, effective Nov 13, 2025.","If terminated without cause, Emerson gets 24 months salary/benefits plus immediate vesting of all unvested equity.","On termination for cause or voluntary quit without good reason, unvested equity forfeited automatically.","Amendment modifies the original Sept 21, 2023 employment agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127265,"accession_number":"0001213900-25-099553","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Apimeds Pharmaceuticals amends bylaws to allow shareholder action by written consent","event_type":"other_material","confidence":"high","bullets":["Board adopted First Amendment to Bylaws on October 15, 2025, effective immediately.","Amendment permits shareholders to take action by written consent without a meeting.","Change provides shareholders an additional mechanism to act outside of annual or special meetings.","No other changes to the bylaws were made; full amendment filed as Exhibit 3.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144057,"accession_number":"0001213900-25-064446","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Apimeds appoints Dr. Susan Kramer SVP Development, Brian Peters to lead ai² division","event_type":"leadership","confidence":"high","bullets":["Dr. Susan Kramer appointed SVP of Development; 30+ years experience including 18 at Genentech.","Brian Peters joins as Head of ai² division; previously Chief Strategy & Insights Officer at Heller Agency.","CEO Erik Emerson says strengthening operational leadership is a priority since IPO.","Dr. Kramer will oversee all product development; Peters will lead ai² platform strategy and launch.","Both appointments effective July 15, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162356,"accession_number":"0001213900-25-051567","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Apimeds Pharmaceuticals appoints Erick J. Frim as CFO, replacing Mark Corrao","event_type":"leadership","confidence":"high","bullets":["Erick J. Frim, 67, appointed CFO effective May 30, 2025, succeeding Mark Corrao.","Mr. Frim has over 40 years of financial management experience, most recently as interim CFO of Helio Corporation.","Compensation: $2,500 per month for first 8 hours, $250 per hour thereafter under a one-year consulting agreement.","No familial relationships or reportable related-party transactions with the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162355,"accession_number":"0001213900-25-045643","cik":1894525,"company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Apimeds extends maturity of three promissory notes to May 19, 2026","event_type":"debt","confidence":"high","bullets":["Amended notes from Inscobee ($100k and $150k) and Apimeds Korea ($250k), total $500k principal.","Original maturity dates extended to May 19, 2026; interest remains 5% per annum.","May 2024 and August 2024 notes were due May 19, 2025; March 2025 note was due Dec 31, 2026 or upon NYSE listing.","Amendments executed on May 16, 2025, avoid imminent default on two notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}